SRR1478946
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.493
- IL6_JAK_STAT3_SIGNALING+0.485
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.469
- INFLAMMATORY_RESPONSE+0.455
- COAGULATION+0.436
- ANGIOGENESIS+0.418
- KRAS_SIGNALING_DN+0.372
- HYPOXIA+0.336
- INTERFERON_GAMMA_RESPONSE+0.326
- MYOGENESIS+0.322
Top 10 suppressed
- MYC_TARGETS_V1-0.540
- PROTEIN_SECRETION-0.511
- OXIDATIVE_PHOSPHORYLATION-0.494
- DNA_REPAIR-0.483
- E2F_TARGETS-0.391
- MYC_TARGETS_V2-0.353
- G2M_CHECKPOINT-0.333
- MITOTIC_SPINDLE-0.274
- UNFOLDED_PROTEIN_RESPONSE-0.262
- FATTY_ACID_METABOLISM-0.211
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1418283 | GTEX | — | 0.957 |
| 2 | SRR1444932 | GTEX | — | 0.950 |
| 3 | SRR1099023 | GTEX | — | 0.946 |
| 4 | BS_3H71BH6Q | Ganglioglioma | — | 0.935 |
| 5 | MDT-AP-0567 | Med | Medulloblastoma | 0.934 |
| 6 | SRR818057 | GTEX | — | 0.933 |
| 7 | SRR1082759 | GTEX | — | 0.932 |
| 8 | BS_PJPGVD62 | EPN | EPN Tumor | 0.931 |
| 9 | SRR1499630 | GTEX | — | 0.930 |
| 10 | SRR1384030 | GTEX | — | 0.928 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.493 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.485 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.469 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.455 | Idelalisib | — uncovered |
| COAGULATION | 0.436 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.418 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.372 | Remibrutinib | — uncovered |
| HYPOXIA | 0.336 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.326 | Idelalisib | — uncovered |
| MYOGENESIS | 0.322 | Inavolisib | — uncovered |
| COMPLEMENT | 0.278 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.277 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.267 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.258 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.248 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.245 | Inavolisib | — uncovered |
| APOPTOSIS | 0.230 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.225 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.218 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.191 | Inavolisib | — uncovered |